Online citations, reference lists, and bibliographies.
← Back to Search

A Potential Therapeutic Strategy For Malignant Mesothelioma With Gene Medicine

Y. Tada, H. Shimada, K. Hiroshima, M. Tagawa
Published 2013 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Malignant mesothelioma, closely linked with occupational asbestos exposure, is relatively rare in the frequency, but the patient numbers are going to increase in the next few decades all over the world. The current treatment modalities are not effective in terms of the overall survival and the quality of life. Mesothelioma mainly develops in the thoracic cavity and infrequently metastasizes to extrapleural organs. A local treatment can thereby be beneficial to the patients, and gene therapy with an intrapleural administration of vectors is one of the potential therapeutics. Preclinical studies demonstrated the efficacy of gene medicine for mesothelioma, and clinical trials with adenovirus vectors showed the safety of an intrapleural injection and a possible involvement of antitumor immune responses. Nevertheless, low transduction efficiency remains the main hurdle that hinders further clinical applications. Moreover, rapid generation of antivector antibody also inhibits transgene expressions. In this paper, we review the current status of preclinical and clinical gene therapy for malignant mesothelioma and discuss potential clinical directions of gene medicine in terms of a combinatory use with anticancer agents and with immunotherapy.
This paper references
10.1200/JCO.2006.09.7634
Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study.
L. Garland (2007)
Serummesothelin for diagnosing malignant pleural mesothelioma: an individual patient datameta-analysis
K. Hollevoet (2012)
Angiogenesis-related factors are molecular targets for diagnosis and treatment of patients with esophageal carcinoma.
Y. Oshima (2010)
10.1200/JCO.2008.20.3943
Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma.
L. Krug (2009)
10.1002/ijc.25197
Inhibition of Met/HGF receptor and angiogenesis by NK4 leads to suppression of tumor growth and migration in malignant pleural mesothelioma
Y. Suzuki (2010)
Gene therapy of established mesothelioma xenogras with recombinant p 16 IIIIIIIII adenovirus
K. Uematsu (2000)
Gene therapy of established mesothelioma xenogras with recombinant p 16 IIIIIIIII adenovirus
K. Uematsu (2000)
10.1210/EN.2005-1006
Endogenous relaxin regulates collagen deposition in an animal model of allergic airway disease.
Ishanee Mookerjee (2006)
10.1002/jgm.1486
Complete regression of human malignant mesothelioma xenografts following local injection of midkine promoter‐driven oncolytic adenovirus
S. Kubo (2010)
p14 í µí°´í µí°´í µí°´í µí°´í µí°´í µí°´µí°´modulates the cytolytic effect of ONYX- 015 in mesothelioma cells with wild-type p53
C T Yang (2001)
10.1038/sj.cgt.7700133
Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: Persistent transgene expression despite antibody generation
S. Mukherjee (2000)
10.1038/ng.912
Germline BAP1 mutations predispose to malignant mesothelioma
J. Testa (2011)
10.1038/bjc.2011.104
Markers for the non-invasive diagnosis of mesothelioma: a systematic review
S. van der Bij (2011)
Jablons, “p14 modulates the cytolytic effect of ONYX- 015 inmesothelioma cells with wild-type p53,”Cancer
C. T. Yang (2001)
10.1200/JCO.20005.14.589
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
J. Van Meerbeeck (2005)
10.1016/j.canlet.2009.05.006
E1B-55kD-deleted oncolytic adenovirus armed with canstatin gene yields an enhanced anti-tumor efficacy on pancreatic cancer.
Xiao-Ping He (2009)
10.1097/JTO.0b013e31817c73d6
Pemetrexed Plus Cisplatin or Pemetrexed Plus Carboplatin for Chemonaïve Patients with Malignant Pleural Mesothelioma: Results of the International Expanded Access Program
A. Santoro (2008)
10.1038/onc.2009.415
A novel translational approach for human malignant pleural mesothelioma: heparanase-assisted dual virotherapy
Y. Watanabe (2010)
Phase II study of erlotinib in patients with malignant pleural mesothelioma: a SouthwestOncologyGroup Study
L. L. Garland (2007)
10.1002/cncr.22477
Novel marker D2‐40, combined with calretinin, CEA, and TTF‐1
T. Mimura (2007)
10.1186/1471-2407-10-54
In vitro and in vivo characterization of highly purified Human Mesothelioma derived cells
A. Melotti (2009)
p14 modulates the cytolytic effect of ONYX-015 in mesothelioma cells with wild-type p53
C T Yang (2001)
10.1038/mt.2009.309
A Phase I Trial of Repeated Intrapleural Adenoviral-mediated Interferon-β Gene Transfer for Mesothelioma and Metastatic Pleural Effusions.
D. Sterman (2010)
10.1074/jbc.M109.025148
Angioinhibitory Action of NK4 Involves Impaired Extracellular Assembly of Fibronectin Mediated by Perlecan-NK4 Association*
K. Sakai (2009)
10.1002/jgm.877
Imaging and therapy of malignant pleural mesothelioma using replication‐competent herpes simplex viruses
P. Adusumilli (2006)
10.1002/cncr.22552
Update on the molecular biology of malignant mesothelioma
A. Lee (2007)
10.1038/NCPCARDIO1089
Is dronedarone effective for the prevention of recurrent atrial fibrillation?
C. White (2008)
10.1016/j.lungcan.2012.05.111
A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma.
J. Dowell (2012)
10.1038/cgt.2011.25
Replication-competent retrovirus vector-mediated prodrug activator gene therapy in experimental models of human malignant mesothelioma
Y. Kawasaki (2011)
10.1038/mt.2010.224
Vesicular stomatitis virus-induced immune suppressor cells generate antagonism between intratumoral oncolytic virus and cyclophosphamide.
C. Willmon (2011)
Update on themolecular biology of malignant mesothelioma,”Cancer
A. Y. Lee (2007)
10.1016/j.lungcan.2008.08.014
Functional inactivation of NF2/merlin in human mesothelioma.
Claudio Thurneysen (2009)
10.1158/0008-5472.CAN-11-3001
Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patients.
S. Pesonen (2012)
10.1056/NEJMRA050152
Advances in malignant mesothelioma.
B. Robinson (2005)
10.1038/mt.2011.230
Verapamil results in increased blood levels of oncolytic adenovirus in treatment of patients with advanced cancer.
A. Koski (2012)
10.2741/3716
Antiangiogenic therapies for malignant pleural mesothelioma.
S. Yano (2011)
10.1038/mt.2010.161
Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF.
A. Koski (2010)
p 14 AAAAAA modulates the cytolytic effect of ONYX015 inmesothelioma cells with wild - type p 53
C. T. Yang (2001)
Gene therapy for malignant pleural mesothelioma : present and future
J. Treat (2008)
10.3727/096504008786991602
Gene therapy for malignant pleural mesothelioma: present and future.
Y. Tada (2008)
10.1007/978-3-642-10862-4
[Malignant mesothelioma].
J. Espinosa Arranz (1994)
10.1111/j.1349-7006.2003.tb01440.x
NK4 (HGF‐antagonist/angiogenesis inhibitor) in cancer biology and therapeutics
K. Matsumoto (2003)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1002/jgm.1578
Intravenous injection of irradiated tumor cell vaccine carrying oncolytic adenovirus suppressed the growth of multiple lung tumors in a mouse squamous cell carcinoma model
Aya Saito (2011)
10.4161/cbt.12.10.17678
Interferon γ improves the vaccination potential of oncolytic parvovirus H-1PV for the treatment of peritoneal carcinomatosis in pancreatic cancer
S. Grekova (2011)
10.1200/JCO.2011.39.6671
Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis.
Kevin Hollevoet (2012)
10.1038/cgt.2011.76
Macrophage metalloelastase (MME) as adjuvant for intra-tumoral injection of oncolytic adenovirus and its influence on metastases development
S. Lavilla-Alonso (2012)
10.1038/mt.2010.22
Verapamil enhances the antitumoral efficacy of oncolytic adenoviruses.
A. Gros (2010)
10.1158/0008-5472.CAN-09-1013
Expression of IFN-beta enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma.
C. Willmon (2009)
10.1089/HUM.2006.17.1152
Development of oncolytic adenovirus armed with a fusion of soluble transforming growth factor-beta receptor II and human immunoglobulin Fc for breast cancer therapy.
P. Seth (2006)
10.1158/0008-5472.CAN-06-1617
Antitumor activity of an oncolytic adenovirus-delivered oncogene small interfering RNA.
Y. Zhang (2006)
10.1164/rccm.201103-0554CR
A trial of intrapleural adenoviral-mediated Interferon-α2b gene transfer for malignant pleural mesothelioma.
D. Sterman (2011)
10.1093/JNCI/92.8.636
Adenovirus-mediated p14(ARF) gene transfer in human mesothelioma cells.
C. Yang (2000)
A comparison analysis of anti-tumor efficacy of adenoviral gene replacement therapy (p14ARF and p16INK4A) in human mesothelioma cells.
Cheng-Ta Yang (2003)
Gene therapy of established mesothelioma xenogras with recombinant p16 í µí°¼í µí°¼í µí°¼í µí°¼í µí°¼í µí°¼í µí°¼í µí°¼í µí°¼ adenovirus
S P Frizelle (2000)
10.1016/j.ctrv.2009.09.003
Second-line treatment for malignant pleural mesothelioma.
G. Ceresoli (2010)
10.1038/sj.cgt.7700241
Gene therapy of established mesothelioma xenografts with recombinant p16INK4a adenovirus
S. P. Frizelle (2000)
10.1038/cgt.2011.86
Upregulated p53 expression activates apoptotic pathways in wild-type p53-bearing mesothelioma and enhances cytotoxicity of cisplatin and pemetrexed
Q. Li (2012)
10.1089/HUM.1998.9.7-1083
Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma.
D. Sterman (1998)
10.1016/S1556-0864(15)30385-3
Targeting Mesothelioma Using an Infectivity Enhanced Survivin-Conditionally Replicative Adenoviruses
Z. Zhu (2006)
Gene therapy of established mesothelioma xenogras with recombinant p 16 IIIIIIIII adenovirus
S. P. Frizelle (2000)
p14ARF Modulates the Cytolytic Effect of ONYX-015 in Mesothelioma Cells with Wild-type p53
C. Yang (2001)
10.1093/JNCI/DJJ397
Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction, and efficacy.
Joo-Hang Kim (2006)
10.1097/JTO.0b013e3182725fa4
E1B-55 kDa-Defective Adenoviruses Activate p53 in Mesothelioma and Enhance Cytotoxicity of Anticancer Agents
M. Yamanaka (2012)
10.1038/SJ.MT.6300264
Human matrix metalloproteinase-8 gene delivery increases the oncolytic activity of a replicating adenovirus.
J. Cheng (2007)
10.1038/cgt.2010.10
Oncolytic measles viruses encoding interferon β and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy
H. Li (2010)
10.1038/cgt.2011.74
Efficient antitumor effects of carrier cells loaded with a fiber-substituted conditionally replicating adenovirus on CAR-negative tumor cells
K. Iguchi (2012)
10.1158/1078-0432.CCR-06-0244
Eliminating Established Tumor in nu/nu Nude Mice by a Tumor Necrosis Factor-α-Related Apoptosis-Inducing Ligand–Armed Oncolytic Adenovirus
F. Dong (2006)
10.1002/jgm.953
A survivin‐mediated oncolytic adenovirus induces non‐apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo
Binghua Li (2006)
10.1038/ncponc1039
Advances in the systemic therapy of malignant pleural mesothelioma
D. Fennell (2008)
p 14 AAAAAA modulates the cytolytic effect of ONYX - 015 inmesothelioma cells with wild - type p 53
C. T. Yang
10.1158/1078-0432.CCR-07-0403
A Phase I Clinical Trial of Single-Dose Intrapleural IFN-β Gene Transfer for Malignant Pleural Mesothelioma and Metastatic Pleural Effusions: High Rate of Antitumor Immune Responses
D. Sterman (2007)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar